Loading
A phase 1/2 trial of CTX112 in hodgkin lymphoma and non-hodgkin lymphoma, run by CRISPR Therapeutics AG, now recruiting.
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT05643742 by CRISPR Therapeutics AG, with 120 participants planned, started 2023-03-10 and due to reach its primary completion in 2030-01. Interventions recorded: CTX112. Conditions listed: B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). No results are recorded here; the registry entry is the source.